Investor Relations

About Abpro

Abpro Corporation is a biotechnology company located in Woburn, Massachusetts. The company’s mission is to improve the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Abpro is advancing the development of its pipeline of its next-generation antibody therapies, including cancer indications, such as HER2+ cancer, for breast, gastric and colorectal cancers, non-HER2+ liver and gastric cancer, in addition to treatments for Wet AMD/DME and infectious diseases. These antibodies are developed using Abpro's proprietary DiversImmune® platform. Abpro has partnered with Celltrion, which is a leading South Korean biotechnology company, in an exclusive collaboration to further advance ABP 102, a t-cell engager, which is being developed for the treatment of HER2+ breast, gastric and pancreatic cancer.